With central banks focused on inflation that has not meaningfully slowed, investors are paying closer attention to cash flows and valuation discipline. When policy makers keep rates in focus, solid cash generation can matter more than short term sentiment swings. This article highlights three stocks from the Undervalued Stocks Based On Cash Flows screener that combine discounted SWS DCF valuations with attractive cash flow potential for patient, value-oriented investors.
The three stocks in this article are only a starting sample, while the full screen surfaced 44 more companies with cash flow profiles and discounted SWS DCF valuations that support equally compelling investment stories not covered here. To identify and analyze those additional opportunities with your own filters, head straight into the Undervalued Stocks Based On Cash Flows screener.
Cochlear (ASX:COH)
Overview: Cochlear develops implantable hearing solutions for children and adults, led by its Nucleus cochlear implant systems and sound processors that anchor a large installed base and long running aftercare needs. The company then builds on those implants with replacement processors, accessories and connected care services that can support recurring cash flows over many years.
Operations: Cochlear generated A$2.35b in revenue from implantable hearing devices, with sales spread across the Americas, EMEA and Asia Pacific.
Market Cap: A$8.9b
Cochlear may be of interest if you want a business where the main product, its cochlear implant systems and Nucleus sound processors, naturally feeds a recurring stream of replacement and aftercare cash flows that suit a DCF style valuation. The stock is currently trading below the Simply Wall St fair value estimate, and FY2026 sales were A$2,347.6 million and analysts expect earnings expansion supported by new products such as the Nexa system and Osia 3. Net income was A$147.3 million, margins are under pressure and a large one off loss has affected recent results. If margins stabilise as upgrades and services increase, the relationship between current pricing and cash flow potential may be a key consideration.
Cochlear’s recurring upgrade cash flows and discounted SWS DCF valuation point to a story that many investors may be only half seeing. Get the fuller picture with the DCF valuation analysis for Cochlear.
Telix Pharmaceuticals (ASX:TLX)
Overview: Telix Pharmaceuticals develops and sells radiopharmaceutical products that help doctors image and treat cancers, with its Illuccix and Gozellix diagnostic agents and late stage TLX591 prostate cancer therapy central to its current cash flow profile. The commercial imaging portfolio provides current revenue while a broad pipeline of prostate, kidney and brain cancer candidates offers potential additional cash flow that underpins the cash flow based valuation theme.
Operations: Telix generated about $705 million from Precision Medicine and $277 million from Manufacturing Solutions, with most revenue coming from the United States at about $872 million.
Market Cap: A$5.3b
Telix Pharmaceuticals combines commercial cash flows with late stage oncology assets that directly contribute to a cash flow based valuation. Illuccix and Gozellix are already supporting revenue in more than 20 countries, while TLX591 and other Phase 3 programs could extend the cash flow profile if trials and approvals progress as planned. However, margins are still thin, funding leans on higher risk sources and the business depends heavily on a small set of key products, so setbacks in trials, pricing pressure or regulatory issues could be significant. For investors who accept those risks, the current discount to SWS DCF value indicates that the market may not be fully reflecting the established imaging franchise and the developing therapeutic pipeline.
Telix Pharmaceuticals is building commercial cash flows while the market debates how much credit to give its late stage oncology pipeline. Get the full story in the 3 key rewards and 2 important warning signs (1 is major!)
Lynas Rare Earths (ASX:LYC)
Overview: Lynas Rare Earths is an integrated rare earths producer that mines ore from its Mt Weld deposit in Western Australia and processes it through facilities in Kalgoorlie and Malaysia to supply light and heavy rare earth oxides used in electric vehicles, wind turbines and other high tech applications. These mining and processing operations are the core source of the company’s cash flows, which underpin its discounted SWS DCF valuation within the Undervalued Stocks Based On Cash Flows screener.
Operations: Lynas Rare Earths generated A$977.9 million from its Rare Earth Operations segment.
Market Cap: A$16.4b
Investors watching cash flow driven opportunities may want Lynas Rare Earths on their radar. The integrated Mt Weld, Kalgoorlie and Gebeng chain is already supporting almost A$1b in annual sales and A$222.35 million in net income, which feeds directly into the discounted cash flow valuation case. At the same time, the stock trades below the SWS DCF fair value while analysts expect strong earnings and revenue growth, so the current price reflects a mix of optimism and caution. Execution risk around downstream expansion, policy shifts in Malaysia and reliance on rare earth pricing all matter. If the cash flows from recent capacity investments prove resilient, the present valuation gap could appear mispriced in hindsight.
Lynas Rare Earths could have cash flows that are out of sync with the stock price. Get under the surface with the analysis report for Lynas Rare Earths to see the risk that might be quietly building.
Seeking Alternatives Before The Crowd
Fresh ideas can move first when momentum builds, prices start breaking out and information decays fast. Do not get caught chasing moves after they are flying. Consider acting before trends are widely recognized.
- Spot cash rich compounders early by scanning companies in the list of solid balance sheet and fundamentals (19 results) while they are still under the radar and before momentum builds.
- Track gold producers when sentiment is dropping elsewhere and use the curated 34 elite gold producer stocks to focus on miners with meaningful scale and resilient operations.
- Follow infrastructure-related opportunities by checking the 38 power grid technology and infrastructure stocks, which filters companies involved in grid technology and high voltage upgrades while these themes remain relevant.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com